Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medivir ABLTS:0GP7 61 Earnings per Share (Diluted) is kr-0.38 as of Jun. 2026. GuruFocus rates LTS:0GP7 with a GF Score™ of 61/100 and a GF Value™ of kr1.24 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Medivir AB ranks better than 61.29% on this metric.
Medivir AB's EPS (Basic) for the
three
months ended in Jun. 2026 was kr-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.38.
Medivir AB's EPS without NRI for the
three
months ended in Jun. 2026 was kr-0.04.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.38.
During the past 3 years, the average EPS without NRIGrowth Rate was 25.10% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 7.70% per year.
During the past 13 years, Medivir AB's highest 3-Year average EPS without NRI Growth Rate was 118.50% per year. The lowest was -51.00% per year. And the median was 15.50% per year.
Medivir AB (LTS:0GP7) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Medivir AB Earnings per Share (Diluted) Related Terms
Medivir AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Medivir AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0GP7 vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Medivir AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medivir AB PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medivir AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Medivir AB's PE Ratio falls into.
Medivir AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Medivir AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr-0.38 mean?
Medivir AB (LTS:0GP7) has a Earnings per Share (Diluted) of kr-0.38 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Medivir AB and its competitors. According to the industry distribution chart, Medivir AB ranks #449 out of 1160 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Medivir AB's Earnings per Share (Diluted) too high?
Medivir AB's current Earnings per Share (Diluted) is kr-0.38. Based on the distribution chart, Medivir AB ranks #449 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medivir AB has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medivir AB ranks #449 out of 1160 companies for Earnings per Share (Diluted). This puts Medivir AB in the upper half of its industry. The industry median Earnings per Share (Diluted) is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Medivir AB and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medivir AB's current Earnings per Share (Diluted) is kr-0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (LTS:0GP7) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.24, compared to a current price of kr1.91 — trading 54% above its estimated fair value. The current Earnings per Share (Diluted) is kr-0.38. Medivir AB's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Medivir AB (LTS:0GP7), the current Earnings per Share (Diluted) is kr-0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medivir AB (LTS:0GP7) Overvalued in 2026?
Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued.
The current stock price of kr1.91 is trading 54% above its estimated GF Value™ of kr1.24.
GuruFocus considers Medivir AB to be Significantly Overvalued.
Key valuation signals for LTS:0GP7:
Earnings per Share (Diluted): kr-0.38
GF Value™: kr1.24 vs. price of kr1.91 (54% above fair value)
No single metric tells the full story. See the LTS:0GP7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
61GF Score
Get the complete analysis for LTS:0GP7
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0GP7 has been successfully added to your 
